Oncoloxía médica

2024

1. A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma

   Frontiers in Immunology, Vol. 15

2. Access to melanoma drugs in Spain: a cross-sectional survey

   Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583

3. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis

   Clinical and Translational Oncology

4. Addressing the data bottleneck in medical deep learning models using a human-in-the-loop machine learning approach

   Neural Computing and Applications, Vol. 36, Núm. 5, pp. 2597-2616

5. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

   Annals of Oncology, Vol. 35, Núm. 9, pp. 805-816

6. Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry

   Archivos de Bronconeumologia

7. Aptamer functionalization effect on the interaction of sphingomyelin nanoemulsions with plasma proteins. A thermodynamic approach

   Journal of Molecular Liquids, Vol. 397

8. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer

   Clinical Lung Cancer, Vol. 25, Núm. 3, pp. 233-243.e8

9. Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

   Journal of Clinical Oncology

10. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

    Lung Cancer, Vol. 194

11. Bilateral Choanal Atresia in a 42-year-old Patient: A Rare Condition Case Report

    Indian Journal of Otolaryngology and Head and Neck Surgery, Vol. 76, Núm. 3, pp. 2789-2792

12. Biomarkers for Pre-Treatment Risk Stratification of Prostate Cancer Patients: A Systematic Review

    Cancers, Vol. 16, Núm. 7

13. Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer

    European Journal of Cancer, Vol. 208

14. Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study

    Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 732-738

15. Catheter – related thrombosis in cancer patients: Data from the registry of thrombosis and nEoplasia of SEOM (TESEO)

    Thrombosis Update, Vol. 17

16. Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients

    Archivos de Bronconeumologia, Vol. 60, Núm. 2, pp. 88-94

17. Controversies in prostate cancer management: Consensus recommendations from experts in northern Spain

    Actas Urologicas Espanolas

18. Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain

    PharmacoEconomics - Open

19. Cribriform morular thyroid carcinoma: Clinicopathological and molecular basis for both a preventive and therapeutic approach for a rare tumor (Review)

    Oncology reports, Vol. 52, Núm. 3

20. Cross-sectional and longitudinal associations of adherence to WCRF/AICR cancer prevention recommendations with health-related quality of life in breast cancer survivors. Health-EpiGEICAM study

    Journal of Nutrition, Health and Aging, Vol. 28, Núm. 8